^
Association details:
| Biomarker: | PIK3CA H1047R |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report
Excerpt:
This case study indicates that combined treatment with everolimus and fulvestrant might be a viable option for the treatment of metastatic breast cancer patients who are HER2 positive and carry a PIK3CA gene mutation…
Secondary therapy:
fulvestrant
DOI:
10.2147/OTT.S104398
